Hvsen Biotechnology Co., Ltd. (300871.SZ)
CNY 11.77
(-0.17%)
CNY 11.77
(-0.17%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 161.37 Million CNY | 18.31% |
| 2022 | 138.22 Million CNY | -14.53% |
| 2021 | 182.64 Million CNY | -13.97% |
| 2020 | 197.73 Million CNY | 95.96% |
| 2019 | 93.44 Million CNY | -7.51% |
| 2018 | 96.09 Million CNY | -4.53% |
| 2017 | 114.37 Million CNY | 83.64% |
| 2016 | 65.91 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 4.81 Million CNY | -88.69% |
| 2024 Q3 | 16.16 Million CNY | -15.29% |
| 2024 Q2 | 19.07 Million CNY | 295.85% |
| 2023 Q1 | 20.52 Million CNY | -56.14% |
| 2023 FY | - CNY | 18.31% |
| 2023 Q4 | 26.87 Million CNY | 396.02% |
| 2023 Q3 | 5.41 Million CNY | 59.61% |
| 2023 Q2 | 3.39 Million CNY | -83.46% |
| 2022 Q2 | 9.08 Million CNY | 32.67% |
| 2022 FY | - CNY | -14.53% |
| 2022 Q1 | 6.84 Million CNY | -14.45% |
| 2022 Q3 | 23.97 Million CNY | 163.98% |
| 2022 Q4 | 46.79 Million CNY | 95.17% |
| 2021 Q4 | 8 Million CNY | -61.92% |
| 2021 FY | - CNY | -13.97% |
| 2021 Q3 | 21.01 Million CNY | -48.59% |
| 2021 Q1 | 76.2 Million CNY | 20.39% |
| 2021 Q2 | 40.88 Million CNY | -46.36% |
| 2020 FY | - CNY | 95.96% |
| 2020 Q4 | 63.3 Million CNY | 13.76% |
| 2020 Q3 | 55.64 Million CNY | 68.99% |
| 2020 Q2 | 32.92 Million CNY | 2.73% |
| 2020 Q1 | 32.05 Million CNY | -27.02% |
| 2019 Q3 | 12.3 Million CNY | 0.0% |
| 2019 Q4 | 43.92 Million CNY | 256.87% |
| 2019 FY | - CNY | -7.51% |
| 2018 FY | - CNY | -4.53% |
| 2017 FY | - CNY | 83.64% |
| 2016 FY | - CNY | 0.0% |